cell non-Hodgkin’s lymphoma
Conditions
Interventions
Experimental group:R-CHOP-21 scheme + Pai-Neng-Da Capsule
Control group:R-CHOP-21 scheme
Sponsors
Lishui Central Municiple Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Those who meet the diagnostic criteria of western medicine for this disease and the diagnostic criteria of TCM deficiency syndrome. All cases were diagnosed as B-cell non-Hodgkin lymphoma by pathological examination and were treated with standard R-CHOP-21 chemotherapy; 2. Aged 18 to 70 years, male or female; 3. The expected survival period is more than 3 months; 4. Quality of life Karnofdky score >= 60 points 5. Blood routine (peripheral blood white blood cell count >= 3.5 × 10^9/L, neutrophil count >= 1.5 × 10^9/L, platelet count >= 100 × 10^9/L, hemoglobin >= 90 g/L); 6. Liver and kidney functions are basically normal. The electrocardiogram was normal. ^
Exclusion criteria
Exclusion criteria: 1. CD5-positive, EBV-positive B-cell lymphoma, pregnant or lactating women, or mentally ill patients; 2. Serum creatinine Cr > 1.5 mg/ml (133 µmol/L) or corrected creatinine clearance 2 times the upper limit of normal); 4. Known allergy to any test drug or drugs with the same chemical structure as the test drug; 5. Combined with any serious disease, which may affect the evaluation of the study; 6. The researchers considered patients with poor compliance, incomplete clinical data and lost patients; 7. Patients receiving radiotherapy at the same time.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| peripheral blood cell count;T cell subsets; | — |
Countries
China
Contacts
Public ContactLi LinJie
Lishui Central Municiple Hospital
Outcome results
None listed